COVID-19 vaccine effectiveness
(Randomized evidence)

Analyses are updated every Friday

Methods

Variants of concern

RCTs

Vaccine types

Overall results (Last update:2021-10-22)

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
EudraCT 2021-002348-57
Pfizer–BioNTech; Moderna; Oxford-AstraZeneca
Bonelli M, medRxiv, 2021

Full text
Commentary
Commentary
Non replicating viral vector

ChAdOx1 booster

BNT or mRNA booster

RCT
*
Adults under current rituximab therapy who did not develop humoral response against SARS-CoV-2 after their standard vaccination with Biontech/Pfizer or Moderna in a single center in Austria N=60
Some concerns
Details

Full description

NCT04400838
AstraZeneca + University of Oxford
Emary K, Lancet, 2021

Full text
Commentary
Non replicating viral vector

ChAdOx1

MenACWY

RCT
Phase 2-3
Adults seronegative at baseline enrolled at 19 study sites in UK N=10673
Some concerns
Details

Full description

NCT04516746
AstraZeneca + University of Oxford
Falsey A, N Engl J Med, 2021

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 3
Adults (22% over 65 years) at high risk for exposure to SARS-CoV-2 and populations at increased risk for Covid-19 complications at 88 sites in USA, Chile, and Peru N=32451
Some concerns
Details

Full description

NCT04324606; ISRCTN15281137
AstraZeneca + University of Oxford
Folegatti PM, Lancet, 2020
COV001

Full text
Commentary
; Commentary
(20)31611-1/fulltext
Non replicating viral vector

ChAdOx1 SD

MenACWY

RCT
Phase 1 - 2
Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK N=1067
Low
Details

Full description

CTRI/2020/08/027170
AstraZeneca + University of Oxford / Serum Institute of India
Kulkarni P, SSRN, 2021

Full text
Commentary
Commentary
Non replicating viral vector

SII-ChAdOx1

Placebo

RCT
Phase 2-3
Adults (seronegative and seropositive)without a history of COVID and not immunocompromised at 14 centers in India N=1200
Some concerns
Details

Full description

CTRI/2020/08/027170
Serum Institute of India / AstraZeneca/Oxford University
Kulkarni P, SSRN, 2021

Full text
Commentary
Commentary
Non replicating viral vector

SII-ChAdOx1

ChAdOx1

RCT
Phase 2-3
Adults (seronegative and seropositive) without a history of COVID and not immunocompromised at 14 centers in India N=401
Some concerns
Details

Full description

ISRCTN69254139, EudraCT: 2020-005085-33
AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma
Liu X, Lancet, 2021
Com-COV

Full text
Commentary
RNA based vaccine

ChAd/BNT

BNT/ChAd

ChAd/ChAd

BNT/BNT

RCT
Phase 2
Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK N=463
Some concerns
Details

Full description

NCT04530396
Gamaleya Research Institute of Epidemiology and Microbiology
Logunov D, Lancet, 2021
RESIST

Full text
Commentary
; Commentary
; Commentary
Non replicating viral vector

GAM-COVID-VAC

Placebo

RCT
Phase 3
SARS-CoV-2- and HIV infection-free adult volunteers at 25 centers in Russia N=21977
Some concerns
Details

Full description

NCT04444674
AstraZeneca + University of Oxford
Madhi S, N Engl J Med, 2021
COV005

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 1-2
Healthy adult volunteers that were HIV-negative and SARS-CoV-2 infection-free in 7 centres in South Africa N=2026
Some concerns
Details

Full description

NCT04444674, PACTR202006922165132
AstraZeneca + University of Oxford
Madhi S, Lancet, 2021

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 1-2
Adults living with HIV in 7 centers in South Africa N=104
Low
Details

Full description

NCT04505722
Janssen Pharmaceutical Companies
Sadoff J, N Engl J Med, 2021
ENSEMBLE

Full text
Commentary
Non replicating viral vector

Ad26.COV2.S

Placebo

RCT
Phase 3
Adults >18 years of age at 213 centers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and USA N=44325
Some concerns
Details

Full description

NCT04436276
Janssen Pharmaceutical Companies
Sadoff J, N Engl J Med, 2021
ENSEMBLE

Full text
Commentary
Non replicating viral vector

Ad26.COV2.S

Ad26.COV2.S 1x10^11vp

Placebo

RCT
Phase 1-2
Healthy SARS-CoV-2 nucleic acid negative adults 18-55 years old and elderly >65 years old in multiple centres in Belgium and the US N=810
Some concerns
Details

Full description

ISRCTN89951424
AstraZeneca + University of Oxford
Voysey M, Lancet, 2020
COV003

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 3
Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil N=10002
Some concerns
Details

Full description

NCT04324606; ISRCTN89951424 ;NCT04400838;NCT044446
AstraZeneca + University of Oxford
Voysey M, Lancet, 2021
COV001/COV002/COV003/COV005

Full text
Commentary
; Commentary
; Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
phase 1/2/3
Adults seronegative at baseline from four studies in multiple centres in Brazil, South Africa, and the UK N=24422
Some concerns
Details

Full description

NCT04400838
AstraZeneca + University of Oxford
Voysey M, Lancet, 2020
COV002

Full text
Commentary
Non replicating viral vector

ChAdOx1 LD/SD

ChAdOx1 SD/SD

Placebo

RCT
Phase 2/3
Healthy adults in 18 centres in the UK N=10673
Some concerns
Details

Full description

NCT04552366
Beijing Institute of Biotechnology, Beijing, China, and CanSino Biologics
Wu S, Lancet, 2021

Full text
Commentary
Non replicating viral vector

Ad5-nCoV 2×10¹⁰ vp mu D0

Ad5-nCoV 2×10¹⁰ vp mu D0

Ad5-nCoV 2×10¹⁰ vp mu D0

Ad5-nCoV 2×10¹⁰ vp mu D0

Ad5-nCoV 1×10¹⁰ vp mu D0

Ad5-nCoV 5×10¹⁰ vp im D0

Ad5-nCoV 5×10¹⁰ vp im D0

Ad5-nCoV 10×10¹⁰ vp im D0

RCT
Phase 1
Adults who were HIV-negative and seronegative for SARS-CoV-2 at a single center in China N=130
Some concerns
Details

Full description

NCT04341389
CanSino Biological Inc./Beijing Institute of Biotechnology
Zhu F, Lancet, 2020

Full text
Commentary
Commentary
Non replicating viral vector

Ad5-vectored 1×10¹¹ vp

Ad5-vectored 1×10¹¹ vp

Ad5-vectored 5×10¹⁰ vp

Ad5-vectored 5×10¹⁰ vp

Placebo

Placebo

RCT
Phase 2
Healthy adult volunteers with HIV-negative and SARS-CoV-2 infection-free in a single centre in China. N=508
Some concerns
Details

Full description